{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:08:01Z","timestamp":1787026081682,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10557-025-07691-4","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T15:44:18Z","timestamp":1744127058000},"page":"225-239","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Interactions Between Direct Oral Anticoagulants and Drugs Involving CYP-Enzymes and P-gp Transporters Detected by a Clinical Decision Support System: A Retrospective Cohort Study"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9511-155X","authenticated-orcid":false,"given":"Stephanie C. M.","family":"Wuyts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Bonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7870-1902","authenticated-orcid":false,"given":"Naomi","family":"Thielemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7770-4143","authenticated-orcid":false,"given":"Fenne","family":"Vandervorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8923-541X","authenticated-orcid":false,"given":"Berlinde","family":"von Kemp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4586-6919","authenticated-orcid":false,"given":"Stephane","family":"Steurbaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2918-9703","authenticated-orcid":false,"given":"Alain G.","family":"Dupont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4802-0241","authenticated-orcid":false,"given":"Pieter","family":"Cornu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"issue":"10","key":"7691_CR1","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","volume":"23","author":"J Steffel","year":"2021","unstructured":"Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612\u201376. https:\/\/doi.org\/10.1093\/europace\/euab065.","journal-title":"Europace"},{"issue":"1","key":"7691_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2165\/00003088-200342010-00003","volume":"42","author":"JH Lin","year":"2003","unstructured":"Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet. 2003;42(1):59\u201398. https:\/\/doi.org\/10.2165\/00003088-200342010-00003.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"7691_CR3","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/pds.3592","volume":"23","author":"S Dechanont","year":"2014","unstructured":"Dechanont S, Maphanta S, Butthum B, et al. Hospital admissions\/visits associated with drug-drug interactions: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2014;23(5):489\u201397. https:\/\/doi.org\/10.1002\/pds.3592.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"7691_CR4","doi-asserted-by":"publisher","unstructured":"Gonzaga de Andrade Santos TN, Mendon\u00e7a da Cruz Macieira G, Cardoso Sodr\u00e9 Alves BM, et al. Prevalence of clinically manifested drug interactions in hospitalized patients: a systematic review and meta-analysis. PLoS One. 2020;15(7):e0235353. https:\/\/doi.org\/10.1371\/journal.pone.0235353","DOI":"10.1371\/journal.pone.0235353"},{"issue":"1","key":"7691_CR5","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12911-020-01376-8","volume":"21","author":"S Taheri Moghadam","year":"2021","unstructured":"Taheri Moghadam S, Sadoughi F, Velayati F, et al. The effects of clinical decision support system for prescribing medication on patient outcomes and physician practice performance: a systematic review and meta-analysis. BMC Med Inform Decis Mak. 2021;21(1):98. https:\/\/doi.org\/10.1186\/s12911-020-01376-8.","journal-title":"BMC Med Inform Decis Mak"},{"key":"7691_CR6","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3233\/shti220101","volume":"290","author":"L Villa Zapata","year":"2022","unstructured":"Villa Zapata L, Subbian V, Boyce RD, et al. Overriding drug-drug interaction alerts in clinical decision support systems: a scoping review. Stud Health Technol Inform. 2022;290:380\u20134. https:\/\/doi.org\/10.3233\/shti220101.","journal-title":"Stud Health Technol Inform"},{"key":"7691_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmedinf.2021.104393","volume":"148","author":"KM Muylle","year":"2021","unstructured":"Muylle KM, Gentens K, Dupont AG, et al. Evaluation of an optimized context-aware clinical decision support system for drug-drug interaction screening. Int J Med Inform. 2021;148: 104393. https:\/\/doi.org\/10.1016\/j.ijmedinf.2021.104393.","journal-title":"Int J Med Inform"},{"issue":"3","key":"7691_CR8","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s11096-014-9925-x","volume":"36","author":"P Cornu","year":"2014","unstructured":"Cornu P, Steurbaut S, Sostaric S, et al. Performance of a clinical decision support system and of clinical pharmacists in preventing drug-drug interactions on a geriatric ward. Int J Clin Pharm. 2014;36(3):519\u201325. https:\/\/doi.org\/10.1007\/s11096-014-9925-x.","journal-title":"Int J Clin Pharm"},{"issue":"9","key":"7691_CR9","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.ijmedinf.2015.05.005","volume":"84","author":"P Cornu","year":"2015","unstructured":"Cornu P, Steurbaut S, Gentens K, et al. Pilot evaluation of an optimized context-specific drug-drug interaction alerting system: a controlled pre-post study. Int J Med Inform. 2015;84(9):617\u201329. https:\/\/doi.org\/10.1016\/j.ijmedinf.2015.05.005.","journal-title":"Int J Med Inform"},{"key":"7691_CR10","unstructured":"Pharmaceutical Information Library (PhiL) [Internet]. Algemene Pharmaceutische Bond (APB). 2024. Available from: https:\/\/phil.apb.be\/nl-BE\/.\u00a0Accessed 2 Nov 2024"},{"key":"7691_CR11","unstructured":"ABDA-Datenbank Interaktionen [Internet]. Avoxa \u2013 Mediengruppe Deutscher Apotheker GmbH. 2024. Available from: https:\/\/abdata.de\/produkte\/abdamed2\/.\u00a0Accessed 2 Nov 2024"},{"issue":"4","key":"7691_CR12","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1586\/ecp.11.30","volume":"4","author":"H Imai","year":"2011","unstructured":"Imai H, Kotegawa T, Ohashi K. Duration of drug interactions: putative time courses after mechanism-based inhibition or induction of CYPs. Expert Rev Clin Pharmacol. 2011;4(4):409\u201311. https:\/\/doi.org\/10.1586\/ecp.11.30.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"7691_CR13","unstructured":"ICH Expert Working Group. ICH Harmonised guideline - M12 Drug Interaction Studies; 2024. Available from: https:\/\/database.ich.org\/sites\/default\/files\/ICH_M12_Step4_Guideline_2024_0521_0.pdf.\u00a0Accessed 2 Nov 2024"},{"key":"7691_CR14","unstructured":"National Institutes of Health. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0: U.S. Department of Health and Human Services; 2017. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf.\u00a0Accessed 2 Nov 2024"},{"issue":"4","key":"7691_CR15","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1345\/aph.1H423","volume":"41","author":"JR Horn","year":"2007","unstructured":"Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007;41(4):674\u201380. https:\/\/doi.org\/10.1345\/aph.1H423.","journal-title":"Ann Pharmacother"},{"key":"7691_CR16","unstructured":"United States Food and Drug Administration (FDA). For healthcare professionals | FDA\u2019s examples of drugs that interact with CYP enzymes and transporter systems Silver Spring, MD (USA): U.S. Department of Health and Human Services: Food and Drug Administration. Available from: https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/healthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems.\u00a0Accessed 2 Nov 2024"},{"issue":"2","key":"7691_CR17","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jcm.2016.02.012","volume":"15","author":"TK Koo","year":"2016","unstructured":"Koo TK, Li MY. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med. 2016;15(2):155\u201363. https:\/\/doi.org\/10.1016\/j.jcm.2016.02.012.","journal-title":"J Chiropr Med"},{"issue":"36","key":"7691_CR18","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","volume":"45","author":"IC Van Gelder","year":"2024","unstructured":"Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314\u2013414. https:\/\/doi.org\/10.1093\/eurheartj\/ehae176.","journal-title":"Eur Heart J"},{"issue":"7","key":"7691_CR19","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1111\/bcp.15265","volume":"88","author":"M Grymonprez","year":"2022","unstructured":"Grymonprez M, Vanspranghe K, Capiau A, et al. Impact of P-glycoprotein and\/or CYP3A4-interacting drugs on effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis. Br J Clin Pharmacol. 2022;88(7):3039\u201351. https:\/\/doi.org\/10.1111\/bcp.15265.","journal-title":"Br J Clin Pharmacol"},{"key":"7691_CR20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.amjcard.2022.10.031","volume":"186","author":"M Shurrab","year":"2023","unstructured":"Shurrab M, Jackevicius CA, Austin PC, et al. Association between concurrent use of amiodarone and DOACs and risk of bleeding in patients with atrial fibrillation. Am J Cardiol. 2023;186:58\u201365. https:\/\/doi.org\/10.1016\/j.amjcard.2022.10.031.","journal-title":"Am J Cardiol"},{"issue":"13","key":"7691_CR21","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1001\/jama.2017.13883","volume":"318","author":"SH Chang","year":"2017","unstructured":"Chang SH, Chou IJ, Yeh YH, et al. Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. JAMA. 2017;318(13):1250\u20139. https:\/\/doi.org\/10.1001\/jama.2017.13883.","journal-title":"JAMA"},{"issue":"8","key":"7691_CR22","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1093\/ehjcvp\/pvad070","volume":"9","author":"M Grymonprez","year":"2023","unstructured":"Grymonprez M, Carnoy L, Capiau A, et al. Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants: a nationwide cohort study. Eur Heart J Cardiovasc Pharmacother. 2023;9(8):722\u201330. https:\/\/doi.org\/10.1093\/ehjcvp\/pvad070.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"8","key":"7691_CR23","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.jfma.2023.02.012","volume":"122","author":"SY Lin","year":"2023","unstructured":"Lin SY, Liu YB, Ho LT, et al. Impact of amiodarone on plasma concentration of direct oral anticoagulant in patients with atrial fibrillation. J Formos Med Assoc. 2023;122(8):776\u201384. https:\/\/doi.org\/10.1016\/j.jfma.2023.02.012.","journal-title":"J Formos Med Assoc"},{"issue":"1370","key":"7691_CR24","first-page":"110","volume":"126","author":"C Fountzilas","year":"2013","unstructured":"Fountzilas C, George J, Levine R. Dabigatran overdose secondary to acute kidney injury and amiodarone use. N Z Med J. 2013;126(1370):110\u20132.","journal-title":"N Z Med J"},{"issue":"5","key":"7691_CR25","doi-asserted-by":"publisher","first-page":"pp","DOI":"10.1093\/europace\/euad083","volume":"25","author":"VC Wu","year":"2023","unstructured":"Wu VC, Wang CL, Huang YC, et al. Cardiovascular outcomes in patients with atrial fibrillation concomitantly treated with antiarrhythmic drugs and non-vitamin k antagonist oral anticoagulants. Europace. 2023;25(5):pp. https:\/\/doi.org\/10.1093\/europace\/euad083.","journal-title":"Europace."},{"issue":"4","key":"7691_CR26","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.3593","volume":"3","author":"P Pham","year":"2020","unstructured":"Pham P, Schmidt S, Lesko L, et al. Association of oral anticoagulants and verapamil or diltiazem with adverse bleeding events in patients with nonvalvular atrial fibrillation and normal kidney function. JAMA Netw Open. 2020;3(4): e203593. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.3593.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"7691_CR27","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.cjco.2021.11.002","volume":"4","author":"K Hill","year":"2022","unstructured":"Hill K, Sucha E, Rhodes E, et al. Amiodarone, verapamil, or diltiazem use with direct oral anticoagulants and the risk of hemorrhage in older adults. CJC Open. 2022;4(3):315\u201323. https:\/\/doi.org\/10.1016\/j.cjco.2021.11.002.","journal-title":"CJC Open"},{"issue":"3","key":"7691_CR28","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/bcp.12075","volume":"76","author":"W Mueck","year":"2013","unstructured":"Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol. 2013;76(3):455\u201366. https:\/\/doi.org\/10.1111\/bcp.12075.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"7691_CR29","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1111\/bcp.13092","volume":"82","author":"DA Parasrampuria","year":"2016","unstructured":"Parasrampuria DA, Mendell J, Shi M, et al. Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine. Br J Clin Pharmacol. 2016;82(6):1591\u2013600. https:\/\/doi.org\/10.1111\/bcp.13092.","journal-title":"Br J Clin Pharmacol"},{"key":"7691_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2020.106304","volume":"162","author":"M Taha","year":"2020","unstructured":"Taha M, Li W, Schmidt CM, et al. The interactions between anticonvulsants and non-vitamin K antagonist oral anticoagulant agents: a systematic review. Epilepsy Res. 2020;162: 106304. https:\/\/doi.org\/10.1016\/j.eplepsyres.2020.106304.","journal-title":"Epilepsy Res"},{"issue":"6","key":"7691_CR31","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1002\/cpt.2369","volume":"110","author":"N Gronich","year":"2021","unstructured":"Gronich N, Stein N, Muszkat M. Association between use of pharmacokinetic-interacting drugs and effectiveness and safety of direct acting oral anticoagulants: nested case-control study. Clin Pharmacol Ther. 2021;110(6):1526\u201336. https:\/\/doi.org\/10.1002\/cpt.2369.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"7691_CR32","doi-asserted-by":"publisher","DOI":"10.1177\/14604582241263242","volume":"30","author":"M Felisberto","year":"2024","unstructured":"Felisberto M, Lima GDS, Celuppi IC, et al. Override rate of drug-drug interaction alerts in clinical decision support systems: a brief systematic review and meta-analysis. Health Informatics J. 2024;30(2): 14604582241263242. https:\/\/doi.org\/10.1177\/14604582241263242.","journal-title":"Health Informatics J"},{"issue":"1","key":"7691_CR33","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1197\/jamia.M2808","volume":"16","author":"MD Paterno","year":"2009","unstructured":"Paterno MD, Maviglia SM, Gorman PN, et al. Tiering drug-drug interaction alerts by severity increases compliance rates. J Am Med Inform Assoc. 2009;16(1):40\u20136. https:\/\/doi.org\/10.1197\/jamia.M2808.","journal-title":"J Am Med Inform Assoc"},{"issue":"2","key":"7691_CR34","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40264-014-0262-8","volume":"38","author":"RT Scheife","year":"2015","unstructured":"Scheife RT, Hines LE, Boyce RD, et al. Consensus recommendations for systematic evaluation of drug-drug interaction evidence for clinical decision support. Drug Saf. 2015;38(2):197\u2013206. https:\/\/doi.org\/10.1007\/s40264-014-0262-8.","journal-title":"Drug Saf"},{"key":"7691_CR35","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.thromres.2020.08.016","volume":"194","author":"A Li","year":"2020","unstructured":"Li A, Li MK, Crowther M, et al. Drug-drug interactions with direct oral anticoagulants associated with adverse events in the real world: a systematic review. Thromb Res. 2020;194:240\u20135. https:\/\/doi.org\/10.1016\/j.thromres.2020.08.016.","journal-title":"Thromb Res"},{"key":"7691_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1332147","volume":"15","author":"C Coumau","year":"2024","unstructured":"Coumau C, Gaspar F, Terrier J, et al. Drug-drug interactions with oral anticoagulants: information consistency assessment of three commonly used online drug interactions databases in Switzerland. Front Pharmacol. 2024;15: 1332147. https:\/\/doi.org\/10.3389\/fphar.2024.1332147.","journal-title":"Front Pharmacol"},{"issue":"11","key":"7691_CR37","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1002\/jcph.2316","volume":"63","author":"DM Burger","year":"2023","unstructured":"Burger DM, le Comte M, Smolders EJ, et al. What the product label does not tell you about drug-drug interaction management: time for a re-appraisal. J Clin Pharmacol. 2023;63(11):1181\u20135. https:\/\/doi.org\/10.1002\/jcph.2316.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"7691_CR38","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s11096-012-9642-2","volume":"34","author":"CS Moura","year":"2012","unstructured":"Moura CS, Prado NM, Belo NO, et al. Evaluation of drug-drug interaction screening software combined with pharmacist intervention. Int J Clin Pharm. 2012;34(4):547\u201352. https:\/\/doi.org\/10.1007\/s11096-012-9642-2.","journal-title":"Int J Clin Pharm"},{"issue":"9","key":"7691_CR39","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1080\/03007995.2017.1347090","volume":"33","author":"S Deitelzweig","year":"2017","unstructured":"Deitelzweig S, Farmer C, Luo X, et al. Risk of major bleeding in patients with non-valvular atrial fibrillation treated with oral anticoagulants: a systematic review of real-world observational studies. Curr Med Res Opin. 2017;33(9):1583\u201394. https:\/\/doi.org\/10.1080\/03007995.2017.1347090.","journal-title":"Curr Med Res Opin"},{"key":"7691_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.583311","volume":"11","author":"M Grymonprez","year":"2020","unstructured":"Grymonprez M, Steurbaut S, De Backer TL, et al. Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-analysis. Front Pharmacol. 2020;11: 583311. https:\/\/doi.org\/10.3389\/fphar.2020.583311.","journal-title":"Front Pharmacol"},{"issue":"1","key":"7691_CR41","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/ehjqcco\/qcad019","volume":"10","author":"M Grymonprez","year":"2024","unstructured":"Grymonprez M, Petrovic M, De Backer TL, et al. Impact of frailty on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a nationwide cohort study. Eur Heart J Qual Care Clin Outcomes. 2024;10(1):55\u201365. https:\/\/doi.org\/10.1093\/ehjqcco\/qcad019.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"7691_CR42","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ahj.2018.09.017","volume":"208","author":"KP Alexander","year":"2019","unstructured":"Alexander KP, Brouwer MA, Mulder H, et al. Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: insights from the ARISTOTLE trial. Am Heart J. 2019;208:123\u201331. https:\/\/doi.org\/10.1016\/j.ahj.2018.09.017.","journal-title":"Am Heart J"},{"issue":"5","key":"7691_CR43","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s10557-019-06907-8","volume":"33","author":"RE Harskamp","year":"2019","unstructured":"Harskamp RE, Teichert M, Lucassen WAM, et al. Impact of polypharmacy and P-glycoprotein- and CYP3A4-modulating drugs on safety and efficacy of oral anticoagulation therapy in patients with atrial fibrillation. Cardiovasc Drugs Ther. 2019;33(5):615\u201323. https:\/\/doi.org\/10.1007\/s10557-019-06907-8.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"8","key":"7691_CR44","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1055\/a-1450-8178","volume":"121","author":"J Douxfils","year":"2021","unstructured":"Douxfils J, Adcock DM, Bates SM, et al. 2021 update of the International Council for Standardization in Haematology recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost. 2021;121(8):1008\u201320. https:\/\/doi.org\/10.1055\/a-1450-8178.","journal-title":"Thromb Haemost"},{"issue":"2","key":"7691_CR45","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/bcp.15017","volume":"88","author":"S Moudallel","year":"2022","unstructured":"Moudallel S, Cornu P, Dupont A, et al. Determinants for under- and overdosing of direct oral anticoagulants and physicians\u2019 implementation of clinical pharmacists\u2019 recommendations. Br J Clin Pharmacol. 2022;88(2):753\u201363. https:\/\/doi.org\/10.1111\/bcp.15017.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"7691_CR46","doi-asserted-by":"publisher","first-page":"pp","DOI":"10.3390\/jcm13072009","volume":"13","author":"D Poli","year":"2024","unstructured":"Poli D, Antonucci E, Ageno W, et al. Inappropriate underdosing of direct oral anticoagulants in atrial fibrillation patients: results from the START2-AF Registry. J Clin Med. 2024;13(7):pp. https:\/\/doi.org\/10.3390\/jcm13072009.","journal-title":"J Clin Med."},{"issue":"3","key":"7691_CR47","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1136\/amiajnl-2012-001089","volume":"20","author":"S Phansalkar","year":"2013","unstructured":"Phansalkar S, van der Sijs H, Tucker AD, et al. Drug-drug interactions that should be non-interruptive in order to reduce alert fatigue in electronic health records. J Am Med Inform Assoc. 2013;20(3):489\u201393. https:\/\/doi.org\/10.1136\/amiajnl-2012-001089.","journal-title":"J Am Med Inform Assoc"},{"issue":"12","key":"7691_CR48","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.34172\/ijhpm.2021.144","volume":"11","author":"S Van Laere","year":"2022","unstructured":"Van Laere S, Muylle KM, Cornu P. Clinical decision support and new regulatory frameworks for medical devices: are we ready for it? - A viewpoint paper. Int J Health Policy Manag. 2022;11(12):3159\u201363. https:\/\/doi.org\/10.34172\/ijhpm.2021.144.","journal-title":"Int J Health Policy Manag"},{"issue":"1","key":"7691_CR49","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2165\/00002018-200831010-00003","volume":"31","author":"TB Agbabiaka","year":"2008","unstructured":"Agbabiaka TB, Savovi\u0107 J, Ernst E. Methods for causality assessment of adverse drug reactions: a systematic review. Drug Saf. 2008;31(1):21\u201337. https:\/\/doi.org\/10.2165\/00002018-200831010-00003.","journal-title":"Drug Saf"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07691-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-025-07691-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07691-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T10:58:45Z","timestamp":1770202725000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-025-07691-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7691"],"URL":"https:\/\/doi.org\/10.1007\/s10557-025-07691-4","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,8]]},"assertion":[{"value":"17 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Medical Ethics Committee of Universitair Ziekenhuis Brussel (UZ Brussel) (Date August 31, 2022\/BUN 1432022000185).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was waived by the Medical Ethics Committee due to the retrospective character of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Financial interests: SCMW, SB, NT, FV, BVK, and AD declare they have no financial interests. PC and SS have received speaker honoraria from Bristol-Myers Squibb Belgium (in 2022). Non-financial interests: The authors have no competing interests to declare that are relevant to the content of this article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}